Literature DB >> 11465408

Colonic drug delivery: prodrug approach.

V R Sinha1, R Kumria.   

Abstract

The colon is largely being investigated as a site for administration of protein and peptides, which are degraded by digestive enzymes in the upper GIT. Also for local diseases of the colon, drug administration to the site of action can not only reduce the dose to be administered, but also decrease the side effects. One of the approaches used for colon specific drug delivery is the formation of a prodrug which optimizes drug delivery and improves drug efficacy. Many prodrugs have been evaluated for colon drug delivery. These prodrugs are designed to pass intact and unabsorbed from the upper GIT and undergo biotransformation in the colon releasing the active drug molecule. This biotransformation is carried out by a variety of enzymes, mainly of bacterial origin present in the colon (e.g. azoreductase, glucuronidase, glycosidase, dextranase, esterase, nitroreductase, cyclodextranase, etc.). The present review includes varius prodrug approaches investigated for colon drug delivery and their site specificity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465408     DOI: 10.1023/a:1011033121528

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  41 in total

1.  Glycosidases in the mammalian alimentary tract.

Authors:  J CONCHIE; D C MACDONALD
Journal:  Nature       Date:  1959-10-17       Impact factor: 49.962

2.  Degradation of dextrans by enzymes of intestinal bacteria.

Authors:  T W SERY; E J HEHRE
Journal:  J Bacteriol       Date:  1956-03       Impact factor: 3.490

Review 3.  Metabolism of foreign compounds by gastrointestinal microorganisms.

Authors:  R R Scheline
Journal:  Pharmacol Rev       Date:  1973-12       Impact factor: 25.468

Review 4.  Intestinal microflora.

Authors:  S L Gorbach
Journal:  Gastroenterology       Date:  1971-06       Impact factor: 22.682

5.  Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats.

Authors:  H W Nolen; R N Fedorak; D R Friend
Journal:  Biopharm Drug Dispos       Date:  1997-11       Impact factor: 1.627

Review 6.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Hydrolysis of ester-type drugs by the purified esterase from human intestinal mucosa.

Authors:  M Inoue; M Morikawa; M Tsuboi; T Yamada; M Sugiura
Journal:  Jpn J Pharmacol       Date:  1979-02

8.  Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid.

Authors:  Y J Jung; J S Lee; H H Kim; Y T Kim; Y M Kim
Journal:  Arch Pharm Res       Date:  1998-04       Impact factor: 4.946

9.  A polymeric drug for treatment of inflammatory bowel disease.

Authors:  J P Brown; G V McGarraugh; T M Parkinson; R E Wingard; A B Onderdonk
Journal:  J Med Chem       Date:  1983-09       Impact factor: 7.446

10.  A budesonide prodrug accelerates treatment of colitis in rats.

Authors:  N Cui; D R Friend; R N Fedorak
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

View more
  17 in total

1.  Characterization of soy polysaccharide and its in vitro and in vivo evaluation for application in colon drug delivery.

Authors:  B M Ursekar; P S Soni; Abhijit A Date; M S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2012-06-28       Impact factor: 3.246

2.  Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery.

Authors:  Dohoon Kim; Wooseong Kim; Seongkeun Jeong; Dayoon Kim; Jin-Wook Yoo; Yunjin Jung
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

3.  Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease.

Authors:  Heejung Kim; Hyesik Kong; Boim Choi; Youngwook Yang; Youngmi Kim; Mi Jung Lim; Len Neckers; Yunjin Jung
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

4.  Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting.

Authors:  Yi-Nuo Pang; Yan Zhang; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 5.  Advances in colonic drug delivery.

Authors:  Abdul W Basit
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Microbial dextran-hydrolyzing enzymes: fundamentals and applications.

Authors:  Elvira Khalikova; Petri Susi; Timo Korpela
Journal:  Microbiol Mol Biol Rev       Date:  2005-06       Impact factor: 11.056

7.  Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.

Authors:  Inho Kim; Hyesik Kong; Younghyun Lee; Sungchae Hong; Jungoh Han; Sunhwa Jung; Yunjin Jung; Young Mi Kim
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

8.  Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers.

Authors:  Jan-Philip Meyer; Kathryn M Tully; James Jackson; Thomas R Dilling; Thomas Reiner; Jason S Lewis
Journal:  Bioconjug Chem       Date:  2018-02-09       Impact factor: 4.774

9.  Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin.

Authors:  Jitendra R Amrutkar; Surendra G Gattani
Journal:  AAPS PharmSciTech       Date:  2009-05-21       Impact factor: 3.246

10.  Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach.

Authors:  Ummarah Kanwal; Shahid Mukhtar; Muzzamil Waheed; Arifa Mehreen; Nasir Abbas; Rahat Shamim; Khalid Hussain; Fatima Rasool; Amjad Hussain; Nadeem Irfan Bukhari
Journal:  Drug Des Devel Ther       Date:  2021-05-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.